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Subarachnoid hemorrhage (SAH) represents a considerable health problem. To date, limited therapeutic options are
available. In order to develop effective therapeutic strategies for SAH, the mechanisms involved in SAH brain
damage should be fully explored. Here we review the mechanisms of SAH brain damage induced by the
experimental endovascular puncture model. We have included a description of similarities and distinctions between
experimental SAH in animals and human SAH pathology. Moreover, several novel treatment options to diminish
SAH brain damage are discussed.
SAH is accompanied by cerebral inflammation as demonstrated by an influx of inflammatory cells into the cerebral
parenchyma, upregulation of inflammatory transcriptional pathways and increased expression of cytokines and
chemokines. Additionally, various cell death pathways including cerebral apoptosis, necrosis, necroptosis and
autophagy are involved in neuronal damage caused by SAH.
Treatment strategies aiming at inhibition of inflammatory or cell death pathways demonstrate the importance of
these mechanisms for survival after experimental SAH. Moreover, neuroregenerative therapies using stem cells are
discussed as a possible strategy to repair the brain after SAH since this therapy may extend the window of
treatment considerably. We propose the endovascular puncture model as a suitable animal model which resembles
the human pathology of SAH and which could be applied to investigate novel therapeutic therapies to combat this
debilitating insult.
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Treatment optionsIntroduction
Subarachnoid hemorrhage (SAH) is a pathological condi-
tion in which arterial blood flows into the subarachnoid
space of the brain and which is mostly caused by a
ruptured aneurysm. SAH occurs at a relatively young
age and has an unpredictable onset. In Western society,
the incidence of SAH is 6 to 7 per 100,000 persons per
year and half of the patients are under the age of 55 [1-4].
SAH is associated with a high mortality rate of 50% [1,4].
In surviving patients the insult has major consequences
for quality of life. In 20 to 40% of the patients who survive* Correspondence: CJHeijnen@mdanderson.org
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stated.the first insult, a second phase of brain damage occurs
which is characterized by delayed cerebral ischemia (DCI)
and is associated with increased morbidity and mortality
[5-7]. DCI, also referred to as delayed ischemic neuro-
logical deficit, is a poorly understood complication of
SAH in patients.
Directly after SAH, an immediate increase in both mean
arterial blood pressure (MABP) and intracranial pressure
(ICP) is observed. Cerebral blood flow (CBF), oxygen
tension, and cerebral perfusion pressure (CPP) decrease dra-
matically after SAH [8-13]. These hemodynamic changes
eventually contribute to initiation of cerebral inflammation
and apoptotic and necrotic cell death. Cerebral vasospasm
is thought to play an important role in the etiology ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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occurring as a result of SAH, like inflammation, oxidative
stress and hemoglobin reacting with nitric oxide (NO),
initiate vasospasm leading to DCI [14]. However, this
hypothesis has been increasingly questioned over the
last couple of years, because vasospasm does not ne-
cessarily lead to DCI and DCI can occur in the absence
of vasospasm [6].
There are only limited therapeutic options available
to diminish brain injury after SAH and unfortunately,
treatments that are available have a short therapeutic
window. In order to design new effective treatment strat-
egies for SAH, the pathophysiology of SAH brain damage
should be studied extensively. The latter necessitates
application of animal models closely resembling human
pathology.
Animal models for SAH
Several animal models of SAH are available, of which the
single-hemorrhage model, the double-hemorrhage model
and the endovascular puncture model are used most com-
monly. In the single-hemorrhage model, a standard amount
(an average of 300 μl) of fresh syngeneic arterial blood is
injected into the cisterna magna [15]. In the double-
hemorrhage model, two injections with autologous arterial
blood are given, in most cases 48 hours apart [15]. In the
endovascular puncture, a suture is placed in the external
carotid artery (ECA) and threaded through the internal
carotid artery up to the middle cerebral artery (MCA)
where the vessel is punctured. The suture is immediately
retracted to limit an ischemic period in order to mimic the
clinical situation as closely as possible. The endovascular
puncture model is mainly performed in rats, although there
are a few studies that describe the endovascular puncture
model in mice. The single- and double-hemorrhage model
is performed in dogs, rabbits, rats and mice. The mortality
rate in the single- and double-hemorrhage experimental
models is low (0 to 20%) and the models are fairly reprodu-
cible because a fixed amount of blood is injected into the
subarachnoid space [10]. In contrast, the mortality of the
endovascular puncture model is higher (approximately 35
to 50%), as in humans. A larger variation in severity of
outcome is also observed, as the extent of the hemorrhage
itself is variable after puncture [6,10,12,16,17]. We would
like to suggest that the endovascular puncture model
resembles human pathology, as an increase in mean
arterial blood pressure and intracranial pressure are ob-
served in both humans and animals after SAH. In the
endovascular puncture model in rats, magnetic resonance
imaging (MRI) showed a modest constriction of blood
vessels two days after SAH, which might mimic vaso-
spasms observed in human SAH pathology [18]. In this
review, our main focus is on the endovascular puncture
experimental model.Aim of this review
The aim of this review is to give an overview of novel
therapeutic approaches to prevent or treat the patho-
logical consequences of SAH. Several other experimental
therapies have been described earlier to combat brain
injury. This review aims at describing a selection of
anti-inflammatory, neuroprotective and neuroregenerative
pathways in the endovascular puncture model. We will
also focus on diagnostic and mechanistic similarities and
distinctions between the endovascular puncture model in
animals and the human pathology of SAH.
Current therapies
The few therapies currently available for SAH focus on
prevention of re-bleeding and prophylaxis for vasospasm
[19-21]. Occlusion of the aneurysm that causes SAH is
usually sought surgically by clipping or by endovascular
coiling. In 5 to 10% of cases, endovascular coiling is not
possible due to morphological characteristics or location of
the aneurysm. However, endovascular coiling is minimally
invasive and therefore, it is preferred over traditional
neurosurgical clipping [20,21]. Hypothermia has been
shown to reduce edema formation and intracranial pressure
after SAH and could be an important means to control
fever in SAH. However, hypothermia has also been associ-
ated with shivering in SAH patients which is negatively
related to outcome after SAH [22,23]. A more invasive
treatment that is sometimes applied is decompressive
craniectomy (DC) aimed at reducing intracranial pressure
after SAH. However, there is continuing debate about
the timing and laterality of DC and on the long-term
consequences [24].
Nimodipine, a calcium channel blocker, is used as a
prophylaxis for vasospasm and treatment with nimodipine
is started for all patients at admission. However, the exact
mechanism of the beneficial effect of nimodipine is un-
known [21]. In addition, treatment with magnesium
sulphate has been associated with a reduction in DCI,
leading to an improvement of clinical outcome. However,
these positive effects of magnesium sulphate have not been
confirmed in all studies [25,26]. The symptomatic
treatment of vasospasm consists of triple H therapy
(hypertension, hypervolemia, and hemodilution) with
the goal of increasing CBF, CPP and to improve blood
flow and oxygen delivery to the cerebral circulation.
Although triple H therapy improves CBF and CPP, it
has not been proven to reduce the incidence of DCI
and mortality [19,21].
Cerebral inflammation after SAH and possible therapeutic
strategies
Influx of immune cells
Inflammation is invariably associated with brain insults
and has been suggested to be a major contributor to
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plasma and cerebrospinal fluid (CSF) have been shown
after SAH [27,28]. In rodents, SAH induces a systemic
increase in pro-inflammatory cytokines and chemokines
[29]. Inflammatory cells like granulocytes and macrophages
are attracted to the injured brain by cerebral production of
chemoattractants and expression of adhesion molecules like
integrins and selectins on endothelial cells, leukocytes,
microglia, and neurons [30,31]. In SAH patients, intercel-
lular and vascular adhesion molecules-1 (ICAM-1 and
VCAM-1) have been shown to be upregulated in both
CSF and serum [32,33].
Moreover, increased blood brain barrier (BBB) perme-
ability after SAH favors influx of peripheral immune cells
into the brain [34]. Matrix metalloproteinase 9 (MMP9)
has been shown to be increased after SAH in the endo-
vascular puncture model [35]. MMP9 is a collagenase
that facilitates transport of immune cells to site of injury
by degrading tight junctions and basal membrane proteins
of the extracellular matrix (ECM) [36].
Macrophages and neutrophils enter the subarachnoid
space early after SAH (within hours) where they activate
resident microglia, astrocytes and neurons [37,38]. Neu-
trophils are primarily engaged in phagocytosis of red
blood cells in the subarachnoid space after which they
degranulate and die [37]. Neutrophils are also detected
in the CSF of SAH patients [39]. Migration to the lesion
site and activation of macrophages/microglia seems to be
an ongoing inflammatory process after SAH; our data show
that active macrophages/microglia can still be detected
even up to three weeks post-SAH in the endovascular
puncture model (Kooijman, et al., unpublished data)
[38,40]. T-cells also enter the damaged area after SAH
but only two days after the SAH [38].
Cytokine production
Activated immune cells secrete cytokines, chemokines,
and reactive oxygen species (ROS). Several cytokines in
the systemic circulation and/or CSF have been reported
to increase after SAH in humans [41-43].
Tumor necrosis factor (TNF)-α is one of the first cy-
tokines that increases after SAH in the endovascular
puncture model. TNF-α regulates various processes:
the expression of other pro-inflammatory cytokines,
immune cell function and trafficking, and initiation of
cell death [44-46]. In the endovascular puncture model,
TNF-α expression has been detected in the cortex after
SAH [40,47]. An increase in TNF-α protein has also
been demonstrated in plasma and CSF of SAH patients
[44-46,48]. Moreover, inhibition of TNF-α via an anti-
TNF-α antibody decreases vasospasm and reduces expres-
sion of pro-apoptotic proteins in the single-hemorrhage
model [49,50]. In line with this, it is interesting to mention
that a phase I study for the use of the TNF-α antagonistetanercept in SAH patients has been started [http://clini-
caltrials.gov/show/NCT01865630].
Interleukin (IL)-6 is secreted as an acute phase protein
by many cell types including macrophages, endothelial
cells, and activated microglia [51,52]. Recently, it has
been shown that IL-6 also stimulates ROS production in
the brain [53]. In the rat endovascular puncture model,
IL-6 is expressed early after SAH [47,54]. To the best of
our knowledge, no specific IL-6 inhibitor has been used in
experimental SAH models. However, the cytokine inhibitor
CNI-1493 (semapimod) inhibits IL-6 and decreases vaso-
spasm in an experimental vasospasm model [55]. There-
fore, CNI-1493 could be a suitable option to investigate
the importance of IL-6 in SAH (see Figure 1).
IL-1β has many functions including induction of pro-
inflammatory cytokines, attraction of leukocytes to the
site of damage and activation of immune cells. There are
contradicting results regarding whether IL-1β expression
is increased in CSF and plasma of SAH patients; some
studies claim no change in IL-1β after SAH [42,56] while
others observed that IL-1β is increased five to nine days
after SAH [41,57]. In the endovascular puncture model,
expression of the precursor- and mature-form of IL-1β
are elevated in the brain after SAH [35,54,58]. Greenhalgh
et al. (2012) showed that next to IL-1β expression, IL-1α
expression is increased in the brain after SAH [59].
The detrimental role of IL-1β in SAH brain damage has
been demonstrated by Sozen et al. (2009) who showed that
Ac-YVAD-CMK, a caspase-1 inhibitor, reduces mortality
after SAH (see Figure 1) [35]. As caspase-1 proteolytically
cleaves the precursor form of IL-1β, Ac-YVAD-CMK
inhibits IL-1β maturation [35,60].
Molecular signaling pathways
Mitogen activated protein (MAP) kinases are important
signaling pathways that are activated by a variety of stress
stimuli and are involved in, for example, regulation of cyto-
kine/chemokine expression. Activation of the MAP kinases
extracellular signal-regulated kinases (ERK) and p38 have
both been reported after experimental SAH [35,54,61,62].
Inhibition of the MEK/ERK pathway by the Raf inhibitor
SB386023-b has been shown to reduce expression of
MMP9 and pro-inflammatory cytokines IL-1β and IL-6
after SAH [62]. In line with this study, inhibition of the
p38 pathway by SB203580 has been shown to reduce
vasospasm, reduce TNF-α expression in CSF, reduce
brain edema and improve behavior after experimental
SAH [60,63].
Cell death mechanisms after SAH and possibilities for
neuroprotection
Apoptosis
Apoptosis is the programmed form of cell death charac-
terized by cell shrinkage, nuclear condensation and DNA
Figure 1 Therapeutic targets and mechanisms of brain damage in human and experimental subarachnoid hemorrhage (SAH).
Schematic overview of known brain damage mechanisms in humans (left side of the figure) and experimental animals models (right side of the
figure). Possible therapeutic options which have been explored in the endovascular puncture model are depicted in light blue. Suggested novel
therapeutic options strategies are depicted in green. The red lines depict the target of inhibition. From top to bottom: SAH induces inflammation
in the brain reflected by increased expression of adhesion molecules, increased influx of immune cells (depicted are neutrophils, macrophages
and T-cells), increased activity of complement system, high mobility group box-1 (HMGB-1) expression, increased expression of transcription
factors and cytokine/chemokine production. Different forms of neuronal cell death after SAH are observed; that is, apoptosis, autophagy, necroptosis
and necrosis. Lower section: physiological factors in the brain which are altered after SAH. Abbreviations: BIP, Bax-inhibiting peptide; CBF, cerebral
blood flow; CPP, cerebral perfusion pressure; EPO, erythropoietin; GA, glycyrrhizic acid; ICP, intracranial pressure; MABP, mean arterial blood pressure;
MSCs, mesenchymal stem cells; NBD, NEMO binding domain peptide; Nec-1, necrostatin-1; OPN, osteopontin; PFT, pifithrin.
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[64]. During apoptosis, activation of the caspase cascade
is a key phenomenon, however, caspase-independent
apoptosis can also be operative [65].
There are numerous reports showing activation of
the extrinsic (death-receptor activated) and intrinsic
(mitochondria-activated) routes of apoptosis after SAH
in the endovascular puncture model but their relative
contribution is still unclear. Several studies show increased
terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining, significant increases in caspase-3,
caspase-8, cytosolic p53 and cytosolic cytochrome c ex-
pression in the brain after SAH in the endovascular punc-
ture model [66,67]. Possibly the severity of SAH directs
the predominant use of the intrinsic or extrinsic route.
Besides elevated levels of pro-apoptotic markers, DNA
fragmentation was also shown to be increased in SAH
rats [67,68]. In contrast, Thal et al. (2009) did not observe
neuronal cell death after SAH [12].
There are several molecules within the apoptotic cascade
that could be targeted for neuroprotection after SAH, for
example, active caspases, p53, the mitochondrial membraneand death receptors [69,70]. We will describe a selection
of strategies aimed at reducing apoptosis at various levels
of the cascade below.
A decrease in apoptotic cell death, including decreased
TUNEL staining, caspase-8 and caspase-3 expression after
experimental SAH has been detected after pre-treatment
with the statin atorvastatin (see Figure 1) [67]. Statins are
already Food and Drug Administration (FDA)-approved
drugs used by patients to lower cholesterol and are also
known to have anti-inflammatory and anti-apoptotic
actions [67]. Atorvastatin has been used in the rat endo-
vascular puncture model using oral administration for
15 days prior to the insult. Although promising, only
the effects of pre-treatment with atorvastatin have been
studied, so it is not clear whether post-SAH treatment
with atorvastatin could also lead to neuroprotection.
If post-treatment with atorvastatin would not convey
protection of cerebral tissue after SAH, the clinical impli-
cation would of course be minimal.
A promising target within the apoptotic cascade may be
represented by p53, a tumor suppressor protein orchestrat-
ing apoptosis at multiple levels. In the nucleus, p53 acts as
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ment with pifithrin (PFT)-α, an inhibitor of transcriptional
activity of p53, resulted in reduction of BBB permeability,
decreased neuronal apoptosis and a decreased mortality
rate in the endovascular puncture model of SAH [72-74].
More recently, a non-transcriptional role of p53 has been
described depending on the association of p53 with mito-
chondria [75]. We have shown that PFT-μ, a specific small
molecule inhibitor of the mitochondrial association of p53
with mitochondria, is potently neuroprotective and has
greater neuroprotective potential than PFT-α treatment
in a neonatal brain damage model [71]. PFT-μ treatment
strongly decreased mitochondrial p53 levels and thereby
significantly inhibited mitochondrial damage, caspase-3
activation and apoptotic cell death after brain damage
[71]. In contrast however, recent studies have shown that
PFT-μ inhibits Heat Shock Protein 70 (HSP70) independ-
ently of p53 in tumor cells [76]. HSP70 is expressed after
cellular stressors like nutrition deprivation and oxidative
stress, and cerebral expression of HSP70 has been shown
to be upregulated in the endovascular puncture model from
day one to day five after SAH and after neonatal ischemic
brain injury [77,78]. Inhibition of HSP70 in leukemic
cells from acute myeloid and acute lymphocytic leukemia
patients has been shown to increase apoptosis and cell
cycle arrest [79,80]. Moreover, Sekihara et al. (2013) have
demonstrated that PFT-μ increases the anti-tumor effects
of hyperthermia via inhibition of HSP70 by promoting a
cell cycle arrest [81]. One explanation for this apparent
discrepancy is that PFT-μ may interfere via inhibition of
HSP70 and by inducing a cell cycle arrest only in actively
cycling tumor cells. Adult neurons are non-dividing cells,
an intracellular state which may divert the mechanistic
action of PFT-μ to prevention of apoptosis. In conclu-
sion, the use of PFT-μ for SAH brain injury seems
promising by its capacity to inhibit neuronal cell death
most probably via prevention of p53 accumulation at
the mitochondria.
Pro- and anti-apoptotic members of the Bcl-2 family
regulate Bax pore formation within the mitochondrial
outer membrane, which is an early key step in setting
of the apoptotic cascade. Moreover, mitochondria are a
source of ROS production under cellular stress conditions.
Several studies have shown that ROS production plays a
role in acute brain injury and vasospasm after SAH and
mitochondrial respiration and activity have been shown to
be disrupted after experimental SAH [82]. Interestingly,
in several studies using the endovascular puncture model,
an increase in mitochondrial Bax expression and other
pro-apoptotic Bcl-2 family members, like PUMA, with
a concomitant release of cytochrome c from the mito-
chondria, was observed after SAH indicating that this
route is operative during SAH-induced brain injury [83-85].
To the best of our knowledge, to date there are no studiesthat directly target Bax pore formation or aim at preserva-
tion of mitochondrial integrity after SAH, whereas this
could be a potent upstream therapeutic target. Wang et
al. (2010) have shown in a model of neonatal ischemic
brain injury that a Bax-inhibiting peptide (BIP) potently
reduced gray- and white matter damage, improved motor
and cognitive behavior, reduced mitochondrial membrane
permeability and subsequent caspase activation [86]. To-
gether these data indicate that the use of BIP could be a
serious option for treating SAH-induced brain injury.
Direct inhibition of caspases is an alternative possibility
to inhibit cerebral apoptosis after SAH. Studies by Zhou
et al., (2004) and Iseda et al., (2007) have shown that
the caspase-3 inhibitor Ac-DEVD-CHO and the broad cas-
pase inhibitor Z-VAD-FMK reduce apoptosis in endothelial
cells and thereby exert an anti-vasospastic effect in the
blood-injection models of SAH in dogs and rabbits [87,88].
Park et al. (2004) has shown in the endovascular puncture
model that treatment with Z-VAD-FMK reduces caspase
activity, BBB permeability, vasospasm, and edema for-
mation in the brain after SAH and improves functional
outcome in rats [89].
A prominent pro-survival pathway is the serine-threonine
kinase Akt. Endo et al. (2006) showed that phosphorylation
of Akt was significantly increased in the endovascular punc-
ture model after SAH. Inhibition of Akt signaling increased
cell damage and apoptotic cell death after SAH [68]. P-Akt
inactivates GSK3β, and P-GSK3β has been shown to be
increased after experimental SAH [68]. We propose inhib-
ition of GSK3β as a realistic therapeutic option for SAH.
Several GSK3β inhibitors are currently being explored, like
lithium and PHA-543613 which is a selective α7nAChR
agonist, activating the PI3-K/Akt pathway and thereby
inhibiting GSK3β. PHA-543613 has been shown to reduce
BBB permeability and increased sensorimotor function after
intracerebral hemorrhage [90].
Necrosis, autophagy and necroptosis
Necrosis is another important form of cell death in the
brain. Necrosis involves unregulated digestion of cell
components, cell swelling, organelle dysfunction and
cell lysis, thereby releasing cellular contents like lysosomes
in the extracellular environment which may promote
inflammation [64,91].
High mobility group box 1 (HMGB1) is a non-histone
DNA-binding protein involved in diverse intracellular
functions such as inflammation and has been described
as being released from necrotic cells [92-94]. Interestingly,
an increase in CSF HMGB1 has been shown in SAH
patients [46]. In line, Murakami et al. (2011) showed
an increase in HMGB1 expression in a rabbit SAH model
using blood injection [95]. HMGB1 released during cell
death may in its turn activate cerebral inflammation by
interacting with the Receptor for Advanced Glycation End
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like TLR2 and TLR4 on microglia and neurons [96]. Apart
from a direct interaction of HMGB1 with its receptors
on the cell, the effects of HMGB1 can be potentiated
by forming stable complexes with endotoxins, thereby
enhancing the potential of HMGB1 to induce a pro-in-
flammatory milieu. Moreover, HMGB1 has been shown to
be capable of enhancing the cleavage of pro-IL-1β to the
mature, active form by activating caspase-1 especially
in a disease relevant condition such as acidosis [97]. In
this respect, it is of interest that a HMGB1 inhibitor,
glycyrrhizic acid (GA), decreases inflammation in several
models of brain damage which may imply that inhibiting
HMGB1 action in SAH might be efficacious to prevent
inflammation and subsequent neuronal damage [98].
Autophagy, which involves secretion of damaged organ-
elles by cells such as macrophages/microglia [99] can either
initiate cell death or be pro-survival [99]. Several studies
showed an early upregulation of autophagy markers after
SAH [100-102]. The positive or negative contribution of
autophagy to brain damage observed after SAH is still
unknown.
Recently, another mechanism of cell death has been de-
scribed named necroptosis, which is a caspase-independent
programmed form of cellular necrosis sharing characteris-
tics of necrosis, apoptosis and autophagy [103]. It has been
shown that necroptosis contributes to brain pathologies
like traumatic brain injury, intracerebral hemorrhage and
neonatal hypoxia-ischemia. Interestingly, in these models
of brain injury, it has been shown that necrostatin-1, a
potent inhibitor of necroptosis, reduced brain damage,
improved behavior, reduced ROS production, reduced
inflammation, preserved mitochondrial function, reduced
caspase-3 activation and reduced markers of autophagy
like LC3-II and Beclin [104-107]. Taken together, targeting
necroptosis seems a promising strategy after SAH as it
may possibly allow the inhibition of multiple routes of cell
death simultaneously.
Molecular targets involved in both inflammation and cell
death: possibilities for neuroprotection
JNK/AP-1 pathway
Inflammation and cell death are closely intertwined as
inflammation often results in cell death and vice versa.
One signaling pathway crucial for regulating both apoptosis
and inflammation is the c-Jun N-terminal kinase (JNK)/
activating protein-1 (AP-1) pathway. The JNK/AP-1 path-
way is activated by a variety of cellular stress stimuli. The
AP-1 transcription factor, when activated by JNK, regu-
lates the upregulation of several pro-inflammatory target
genes, like several cytokines and chemokines, as well as
pro-apoptotic target genes, like Fas [108]. Moreover, JNK
has been shown to phosphorylate several key players
within the apoptotic cascade, like p53, PARP-1, Bcl-2and Bcl-xL and Bim, which facilitates the induction of
apoptosis.
Phosphorylation of JNK, as a marker of activation of
the JNK/AP-1 pathway, is induced in brain tissue in
the endovascular puncture model [35]. Treatment with
Ac-YVAD-CMK treatment, a caspase-1 inhibitor, reduces
JNK phosphorylation, leading to downregulation of the
pro-inflammatory response [35]. Inhibition of JNK by
SP600125, an ATP-competitive JNK inhibitor, results
in neuroprotection measured as a decrease of cell death as
shown by TUNEL staining and decreased cleaved caspase-
3, reduced edema formation and BBB leakage, reduced
MMP9 and improved functional outcome in the endovas-
cular puncture model [109]. Additionally, in the blood
injection model of SAH, it has also been shown that
SP600125 can reduce caspase-3 activation, vasospasm,
infiltration of leukocytes and IL-6 production [110,111].
More recently, a specific small peptide inhibitor of the
JNK pathway, D-JNKi, has been shown to be neuroprotec-
tive in several brain damage models [112-116]. D-JNKi
prevents interaction of JNK with its downstream and
upstream targets, like the AP-1 transcription factor and
MKK4/7 respectively. Moreover, D-JNKi was shown to
strongly inhibit activation of mitochondrial JNK, which
was identified as an important first step in setting off the
apoptotic cascade [117]. Neuroprotection by D-JNKi in
several models of brain injury is strongly associated with
inhibition of pro-inflammatory cytokine/chemokine ex-
pression, inhibition of apoptotic cell death, reduction of
brain injury and improvement of motor and cognitive
behavior (see Figure 1) [112-116]. These data together
indicate that inhibition of the JNK pathway might lead
to inhibition of both inflammatory and cell death pathways,
which might greatly enhance the efficacy of treatment.
NF-κB pathway
Nuclear factor-kappa B (NF-κB) is another transcription
factor that regulates gene expression involved in inflam-
mation, cell survival and apoptosis. NF-κB can increase
pro-apoptotic factors in neurons and glial NF-κB activa-
tion induces expression of pro-inflammatory cytokines
[118,119]. NF-κB seems to be a key regulator in the
formation of cerebral aneurysms, which are probably
at the origin of SAH [120,121]. SAH increases NF-κB
activation in the brain during SAH in the endovascular
puncture model, which is associated with an increased
production of several inflammatory mediators [54,61,121].
You et al. (2013) have shown in the double-hemorrhage
model of SAH that inhibition of NF-κB by PDTC, a prote-
asome inhibitor, reduces TNF-α, IL-1β and ICAM mRNA
expression after SAH [121]. A more specific NF-κB inhibi-
tor could be TAT-NBD, a small peptide inhibitor of the in-
hibitory kappa B kinase (IKK)/NF-κB pathway. TAT-NBD
has been shown to strongly reduce neonatal brain injury,
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term motor and cognitive behavioral outcome [122,123].
Moreover, we have shown previously that TAT-NBD
strongly reduced apoptotic cell death, that is, caspase-3
activation and cytochrome c leakage, after ischemic brain
injury [122,123].
Of interest, the possible effect of NF-κB inhibition
and thereby the reduction of inflammation in SAH has
also been shown by Suzuki et al. using recombinant-
osteopontin (r-OPN) an endogenous extracellular matrix
glycoprotein which is actively secreted after brain injury
[61,124]. Besides NF-κB inhibition, OPN acts as a growth
factor, increasing neural progenitor cell (NPC) proliferation
and differentiation, allowing r-OPN to be a theoretically
suitable therapy [125]. Suzuki et al. (2010) showed that
r-OPN reduced NF-κB activation and MMP-9 expression
in the endovascular puncture model [61]. Furthermore,
r-OPN treatment improved the neurological score and
decreased BBB permeability after SAH. In general, an
increase in permeability of the BBB contributes to in-
flammation and neuronal damage, since it facilitates the
trafficking of inflammatory cells and mediators across
the BBB. MMP-9 favors BBB permeability by degrading
the ECM. However, although the neurological score was
improved early after SAH after r-OPN treatment, there
was no significant difference in mortality between vehicle-
treated animals and r-OPN-treated animals. Important to
note is that besides the role of NF-κB in damaging path-
ways, NF-κB can also promote survival in neurons by the
increase of anti-oxidants and anti-apoptotic molecules
[119]. Thereby, NF-κB can have a dual role in brain
damage and inhibition of NF-κB could reduce neuronal
survival indicating that besides inhibiting inflamma-
tion, a more pronounced inhibition of cell death might
be necessary to effectively decrease brain damage and
mortality [61]. Since the NF-κB pathway is a classic ex-
ample of a regulatory pathway of both inflammation and
cell death, inhibition of this pathway by a specific inhibitor
like TAT-NBD might be promising (see Figure 1).
Possible neuroregenerative strategies
An important drawback of neuroprotective interventions
is the relatively short therapeutic window. Therefore, ther-
apies to repair the already damaged brain would be an
interesting goal for treatment of SAH patients.
Erythropoietin (EPO), a sialoglycoprotein, has recently
been suggested as a possible therapeutic option for SAH
[126-128]. EPO has been shown to reduce brain injury in
various types of cerebral insults [128-132]. EPO enhances
neurogenesis as a neuronal growth factor, but EPO can
also counteract inflammation and apoptosis [133-137].
With respect to SAH, Grasso et al. (2002) and Cheng
et al. (2009) showed that treatment with rhEPO improves
neurological outcome and decreases cell death after SAH[138,139]. To our knowledge, rhEPO has not been tested
in the endovascular puncture model. Interestingly, Helbok
et al. (2012) showed in a pilot study that EPO increases
cerebral blood flow and oxygen delivery to the brain after
SAH in humans [127]. Especially in SAH patients with a
severe lesion, EPO is suggested to have beneficial effects
on outcome [127]. These data indicate that EPO might
become a safe and realistic option for treatment of
patients with SAH, but the robustness of the therapy
still has to be proven in a larger study (Figure 1).
Another potential neuroregenerative strategy could be
the use of stem cell transplantation. Mesenchymal stem
cells (MSCs) are known to interact with many cell types
in the brain, like neural stem cells, cerebral endothelial
cells, astrocytes and neurons, thereby boosting endogen-
ous neurogenesis, repair and axonal sprouting [140]. In
several brain damage models, mortality and lesion size
were decreased after MSC transplantation [140-146]. In
mice, MSCs can be administered as late as ten days after
induction of neonatal brain damage, underpinning the
long time-window of MSC transplantation [147]. Another
advantage is that the intranasal route can be used for
MSC administration allowing a rapid, and effective route
of administration [144,147]. Khalili et al. (2012) showed
in a SAH model of autologous blood injection that MSC
transplantation at 24 hours after SAH improves neurological
function [148]. Preliminary experiments in our group indi-
cate that MSC also improve neurological functioning in
the endovascular puncture model, suggesting that MSC
transplantation may become a promising therapy for SAH
with a long time window (Figure 1) [146,147].
It is of importance to note that strategies aiming at inhib-
ition of pro-inflammatory cytokine expression, including
those described above, could potentially result in reduced
neuroregeneration [149,150]. Synthesis of cytokines
and growth factors is necessary for proliferation and
differentiation of neural precursor cells (NPC) [149,150].
Moreover, inflammatory cells are responsible for migration
of neuronal precursor cells towards the side of damage by
the expression of cytokines and chemokines.
Towards clinical application
The studies reviewed here indicate that inflammation,
as well as activation of multiple cell death pathways are
important contributors to development of SAH brain
injury. In this paper we review a hypothesis-driven se-
lection of strategies that could potentially be used to
combat SAH brain damage. We have focused on the
endovascular puncture model as this animal model
closely mimics SAH pathology in humans. The currently
known inflammatory responses and cell death mechanisms
that we described to be operative in the endovascular
model of SAH are to a large extent also operative in other
experimental models of SAH.
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egies described in this review will be most effective when
the drugs allow administration with a therapeutic window
of at least a few hours. Moreover, as brain injury after
SAH develops as a result of an interplay of several detri-
mental pathways, including inflammation and multiple
routes of cell death, we suggest that neuroprotective
inhibitors that target both inflammation and cell death,
like D-JNKi or TAT-NBD, are promising candidates to
combat SAH brain injury. When targeting cell death
specifically, a strategy targeting the upstream in the
apoptotic cascade, for example, PFT-μ, D-JNKi or BIP,
would be preferable. These drugs inhibit damage to the
mitochondrial outer membrane, thereby preventing ac-
tivation of the downstream cascade, which is a more
realistic option than targeting one specific caspase in
the cascade. In this respect, it is important to realize
that several forms of cell death might be operative in the
SAH injured brain, so the use of necrostatin-1, which has
been shown to inhibit multiple cell death pathways might
also be a promising candidate.
Finally, we would like to underline the importance of
neuroregenerative strategies like intranasal MSC adminis-
tration to repair cerebral injury induced by SAH, especially
when treatment cannot be started within a few hours after
the insult. Moreover, regenerative strategies could also
be considered as an add-on therapy of neuroprotective
strategies for enhancing tissue repair.Abbreviations
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